60 Quick summary: Researchers have discovered a critical cellular vulnerability in approximately 90% of pancreatic cancers where oncogenic gene mutations prime tumour cells for inflammatory self destruction. By blocking a specific protective protein that currently keeps these malignant cells alive, scientists successfully reduced early stage lesions and prolonged survival rates in preclinical testing models. This breakthrough carries major public policy and healthcare practice implications by offering a viable targeted therapeutic strategy for an exceptionally aggressive disease, offering renewed hope for patient well-being and future clinical trial designs. Researchers at the University of Cologne have identified a previously unknown weakness in most pancreatic cancer cells that could be exploited to trigger their self-destruction, opening new perspectives for treating one of the most aggressive and difficult-to-treat cancers. Pancreatic cancer carries mutations in the KRAS gene in approximately 90% of cases, driving tumour growth and contributing to the disease’s poor response to available treatments. Due to the ageing population and the lack of effective therapies, pancreatic ductal adenocarcinoma, the most common form of the disease, is projected to become the second-leading cause of cancer-related death within this decade. The team, led by Professor Silvia von Karstedt at the Center for Molecular Medicine Cologne (CMMC), found that cancer cells harbouring KRAS mutations continuously activate signals from the innate immune system, specifically through the cGAS–STING–TBK1 axis, which induces a type I interferon response. This primes the cells for necroptosis, an inflammatory form of cell death. To survive, tumour cells rely heavily on the protein, which normally inhibits this process. Blocking caspase-8 causes the tumour cells to die. “KRAS-mutated tumours have a previously unknown Achilles’ heel,” said von Karstedt, senior author of the study. “By switching off the tumour cells’ defence mechanisms, we can significantly increase the killing of these tumour cells.” In genetically modified mouse models, depleting caspase-8 to induce necroptosis led to a significant reduction in precursor lesions, the abnormal tissue from which malignant tumours can develop. A combination drug therapy using agents already in clinical use also significantly reduced tumour growth and prolonged the animals’ survival. The approach was further validated in patient-derived tumour organoids, three-dimensional mini-tumours grown from human pancreatic cancer tissue, where it showed significant efficacy, suggesting promise for future clinical trials. “The findings provide strong evidence that certain forms of pancreatic cancer could be specifically targeted for treatment based on their dependence on caspase-8,” said first author Sofya Tishina, a postdoctoral researcher in von Karstedt’s lab. “In the long term, this could help develop new therapies for patients who currently have very limited treatment options.” The study, “Oncogenic KRAS-Driven type I Interferon Signalling Primes Pancreatic Cancer for Necroptosis,” published in Nature Communications, involved scientists from the German Consortium for Translational Cancer Research (DKTK), the Technical University of Munich, and other national and international partners, and was funded by German Cancer Aid, the German Research Foundation (DFG), the former Federal Ministry of Education and Research (BMBF), and the CMMC. Further studies will be needed to optimise drug combinations, assess safety in humans, and identify biomarkers for patients most likely to benefit. Nevertheless, the identification of this vulnerability in KRAS-mutated pancreatic tumours marks an important advance in the search for better outcomes for patients facing this devastating disease.